Učitavanje...

The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

BACKGROUND: Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Wilson, Caroline, Ottewell, Penelope, Coleman, Robert E, Holen, Ingunn
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4329195/
https://ncbi.nlm.nih.gov/pubmed/25884855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1066-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!